Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IA4G
|
|||
| Drug Name |
PMID25656651-Compound-37a
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
NOVARTIS AG DODD, Stephanie Kay FURET, Pascal GROTZFELD, Robert Martin JAHNKE, Wolfgang JONES, Darryl Brynley MANLEY, Paul MARZINZIK, Andreas PELLE, Xavier Francois Andre SALEM, Bahaa SCHOEPFER, Joseph
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H18ClF3N4O3
|
|||
| Canonical SMILES |
C1CN(CC1O)C2=C(C=C(C=C2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=C(C=NN4)F
|
|||
| InChI |
1S/C21H18ClF3N4O3/c22-21(24,25)32-15-4-2-13(3-5-15)27-20(31)12-1-6-18(29-8-7-14(30)11-29)16(9-12)19-17(23)10-26-28-19/h1-6,9-10,14,30H,7-8,11H2,(H,26,28)(H,27,31)/t14-/m1/s1
|
|||
| InChIKey |
XFHOXKYPYFGBCJ-CQSZACIVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.